7 August 2018 - Hemlibra is the first new treatment in almost 20 years for this most severe form of haemophilia and the only medicine that is self-injected once weekly.

Roche Canada announced today that Health Canada has approved Hemlibra (emicizumab injection) for haemophilia A (congenital factor VIII deficiency) patients with factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes.

In two of the largest clinical studies for people with haemophilia A with inhibitors (HAVEN 1 and HAVEN 2), Hemlibra was shown to substantially reduce bleeds in adults and children compared to prior episodic (on demand) treatment with bypassing agents.

Read Roche press release